COVID-19 Vaccination prevents development of long Covid: BMJ
A recent study published in the British Medical Journal explored the impact of primary COVID-19 vaccination on post-COVID-19 conditions (PCC). The study spanned from December 2020 to February 2022 as part of the Swedish Covid-19 Investigation for Future Insights. This involved 589,722 adults in Sweden, sheds light on the effectiveness of the initial two doses and the first booster shot within the recommended schedule.
Out of the 299,692 vaccinated individuals who were infected with COVID-19 during the study, only 0.4% received a diagnosis of PCC during follow-up. This contrasts with the 1.4% of the 290,030 unvaccinated individuals who developed post-COVID conditions. The vaccination strategy, irrespective of the number of doses, demonstrated a substantial reduction in the risk of PCC, with a calculated vaccine effectiveness of 58%.
The breakdown of vaccine effectiveness by dosage found that individuals who received one dose showed 21% effectiveness against PCC, while those with two doses demonstrated a robust 59% reduction in risk. Individuals who received three or more doses experienced an even more significant reduction, with a vaccine effectiveness of 73%.
The study adjusted for various factors, including age, sex, comorbidities, healthcare contacts, socioeconomic factors, and the dominant virus variant at the time of infection. These results underscore the crucial role of primary COVID-19 vaccination in mitigating the population burden of post-COVID conditions.
Despite the positive findings, the study emphasizes the need for ongoing caution and adherence to evidence-based, standard-of-care treatments. While the association between COVID-19 vaccination and reduced PCC risk is strong, researchers call for continued research, especially large-scale clinical trials, to further solidify these conclusions and address any remaining uncertainties.
Reference:
Lundberg-Morris, L., Leach, S., Xu, Y., Martikainen, J., Santosa, A., Gisslén, M., Li, H., Nyberg, F., & Bygdell, M. (2023). Covid-19 vaccine effectiveness against post-covid-19 condition among 589 722 individuals in Sweden: population based cohort study. In BMJ (p. e076990). BMJ. https://doi.org/10.1136/bmj-2023-076990
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.